Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

19.02.2024

7 Antiviral Res
5 BMJ
1 Epidemiol Infect
2 J Clin Microbiol
1 J Infect Dis
4 J Virol
1 JAMA
4 Lancet
2 PLoS Comput Biol
21 PLoS One
17 Vaccine
2 Virus Res



    Antiviral Res

  1. ZHANG X, Xia Y, Li P, Wu Z, et al
    Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus.
    Antiviral Res. 2024 Feb 11:105822. doi: 10.1016/j.antiviral.2024.105822.
    >> Share

  2. IZMAILYAN R, Matevosyan M, Khachatryan H, Shavina A, et al
    Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results.
    Antiviral Res. 2024;222:105818.
    >> Share

  3. BOUZIDI HS, Driouich JS, Klitting R, Bernadin O, et al
    Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
    Antiviral Res. 2024 Jan 23:105814. doi: 10.1016/j.antiviral.2024.105814.
    >> Share

  4. IDRIS A, Supramaniam A, Tayyar Y, Kelly G, et al
    An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.
    Antiviral Res. 2024;222:105815.
    >> Share

  5. RICHTER M, Doring K, Blaas D, Riabova O, et al
    Molecular mechanism of rhinovirus escape from the Pyrazolo[3,4-d]pyrimidine capsid-binding inhibitor OBR-5-340 via mutations distant from the binding pocket: Derivatives that brake resistance.
    Antiviral Res. 2024;222:105810.
    >> Share

  6. GOVEDNIK T, Lainscek D, Kuhar U, Lachish M, et al
    TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences.
    Antiviral Res. 2024 Jan 9:105806. doi: 10.1016/j.antiviral.2024.105806.
    >> Share

  7. LOAIZA RA, Ramirez RA, Sepulveda-Alfaro J, Ramirez MA, et al
    A molecular perspective for the development of antibodies against the human respiratory syncytial virus.
    Antiviral Res. 2024;222:105783.
    >> Share


    BMJ

  8. MCGREGOR G, Sandhu H, Bruce J, Sheehan B, et al
    Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial.
    BMJ. 2024;384:e076506.
    >> Share

  9. HINMAN RS, Maher CG
    Rehabilitation for post-covid-19 condition.
    BMJ. 2024;384:q20.
    >> Share

  10. IACOBUCCI G
    Long covid: Online rehabilitation can improve quality of life, study reports.
    BMJ. 2024;384:q346.
    >> Share


  11. Seven days in medicine: 31 Jan to 6 Feb 2024.
    BMJ. 2024;384:q299.
    >> Share

  12. CIPRIANO CB, Kadakia KT, Chokshi DA
    Is the US prepared for the next pandemic? No, but it could be.
    BMJ. 2024;384:q332.
    >> Share


    Epidemiol Infect

  13. YAMAYOSHI S, Nagai E, Mitamura K, Hagihara M, et al
    Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan.
    Epidemiol Infect. 2024;152:e24.
    >> Share


    J Clin Microbiol

  14. DURANT TJS, Peaper DR
    Retrospective evaluation of clinical decision support for within-laboratory optimization of SARS-CoV-2 NAAT workflow.
    J Clin Microbiol. 2024;62:e0078523.
    >> Share

  15. PFAU B, Opsahl J, Crew R, Best S, et al
    Tiny swabs: nasal swabs integrated into tube caps facilitate large-scale self-collected SARS-CoV-2 testing.
    J Clin Microbiol. 2024;62:e0128523.
    >> Share


    J Infect Dis

  16. AMINISANI N, Wood T, Jelley L, Wong C, et al
    The burden of HMPV and influenza associated hospitalizations in adults in New Zealand, 2012-2015.
    J Infect Dis. 2024 Feb 13:jiae064. doi: 10.1093.
    >> Share


    J Virol

  17. NIE L, Huang Y, Cheng Z, Luo H, et al
    An intranasal influenza virus vector vaccine protects against Helicobacter pylori in mice.
    J Virol. 2024 Feb 15:e0192323. doi: 10.1128/jvi.01923.
    >> Share

  18. ZENG J, Du F, Xiao L, Sun H, et al
    Spatiotemporal genotype replacement of H5N8 avian influenza viruses contributed to H5N1 emergence in 2021/2022 panzootic.
    J Virol. 2024 Feb 15:e0140123. doi: 10.1128/jvi.01401.
    >> Share

  19. THOMAS MN, Zanella GC, Cowan B, Caceres CJ, et al
    Nucleoprotein reassortment enhanced transmissibility of H3 1990.4.a clade influenza A virus in swine.
    J Virol. 2024 Feb 14:e0170323. doi: 10.1128/jvi.01703.
    >> Share

  20. KATAYAMA M, Murakami S, Ishida H, Matsugo H, et al
    Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein among influenza D virus lineages revealed using epitope mapping.
    J Virol. 2024 Feb 12:e0190823. doi: 10.1128/jvi.01908.
    >> Share


    JAMA

  21. RAGLOW Z, Malani PN, Petty LA
    Outpatient Treatment for COVID-19.
    JAMA. 2023 Aug 16. doi: 10.1001/jama.2023.16666.
    >> Share


    Lancet

  22. DELFRAISSY JF, Horgan M, Molbak K, Simon FS, et al
    Scientific advisory councils in the COVID-19 response.
    Lancet. 2023 Oct 12:S0140-6736(23)01846-9. doi: 10.1016/S0140-6736(23)01846.
    >> Share


  23. Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2024 Jan 12:S0140-6736(23)02467-4. doi: 10.1016/S0140-6736(23)02467.
    >> Share

  24. GULLIFORD MC, Steves CJ
    Access to COVID-19 vaccination and COVID-19-related hospital admissions and mortality.
    Lancet. 2024 Jan 12:S0140-6736(23)02622-3. doi: 10.1016/S0140-6736(23)02622.
    >> Share

  25. ADERINTO N, Olatunji G, Kokori E
    Health implications of GSK's departure from Nigeria.
    Lancet. 2024;403:526-527.
    >> Share


    PLoS Comput Biol

  26. VAN BOVEN M, van Dorp CH, Westerhof I, Jaddoe V, et al
    Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study.
    PLoS Comput Biol. 2024;20:e1011832.
    >> Share

  27. CHAN LYH, Ro G, Midtbo JE, Di Ruscio F, et al
    Modeling geographic vaccination strategies for COVID-19 in Norway.
    PLoS Comput Biol. 2024;20:e1011426.
    >> Share


    PLoS One

  28. LAOR T
    Public and commercial more of the same? The characteristics of the opening monologues of public and commercial channels during the COVID-19 pandemic.
    PLoS One. 2024;19:e0293172.
    >> Share

  29. GONG Z, Wang Y, Li M
    Determining the drivers of global innovation under COVID-19: An FSQCA approach.
    PLoS One. 2024;19:e0295403.
    >> Share

  30. ROSENBERG A, Puglisi LB, Thomas KA, Halberstam AA, et al
    "It's just us sitting there for 23 hours like we done something wrong": Isolation, incarceration, and the COVID-19 pandemic.
    PLoS One. 2024;19:e0297518.
    >> Share

  31. MCCABE EM, Luk JW, Stangl BL, Schwandt ML, et al
    Exercising healthy behaviors: A latent class analysis of positive coping during the COVID-19 pandemic and associations with alcohol-related and mental health outcomes.
    PLoS One. 2024;19:e0297060.
    >> Share

  32. BOSTAN ALI W, Olayinka JA, Alam MM, Immelman A, et al
    Assessing economic implications for micro, small and medium enterprises in Thailand post Covid-19 lockdown.
    PLoS One. 2024;19:e0294890.
    >> Share

  33. GORGELS KMF, van Iersel SCJL, Keijser SFA, Hoebe CJPA, et al
    Estimating infection prevalence using the positive predictive value of self-administered rapid antigen diagnostic tests: An exploration of SARS-CoV-2 surveillance data in the Netherlands from May 2021 to April 2022.
    PLoS One. 2024;19:e0298218.
    >> Share

  34. SHIROSHITA A, Gebretsadik T, Wu P, Kubilay NZ, et al
    Association between age of respiratory syncytial virus infection hospitalization and childhood asthma: A systematic review.
    PLoS One. 2024;19:e0296685.
    >> Share

  35. MORENO-JUSTE A, Poblador-Plou B, Ortega-Larrode C, Laguna-Berna C, et al
    Mental health and risk of death and hospitalization in COVID-19 patients. Results from a large-scale population-based study in Spain.
    PLoS One. 2024;19:e0298195.
    >> Share

  36. CHEN TL, Chou EP, Chen MY, Hsieh F, et al
    Unraveling implicit human behavioral effects on dynamic characteristics of Covid-19 daily infection rates in Taiwan.
    PLoS One. 2024;19:e0298049.
    >> Share

  37. CILDOZ M, Gaston M, Frias L, Garcia-Vicuna D, et al
    Early detection of new pandemic waves. Control chart and a new surveillance index.
    PLoS One. 2024;19:e0295242.
    >> Share

  38. ASAMOAH I, Adusei-Poku M, Vandyck-Sey P, Steele-Dadzie A, et al
    COVID-19 in patients presenting with malaria-like symptoms at a primary healthcare facility in Accra, Ghana.
    PLoS One. 2024;19:e0298088.
    >> Share

  39. VAN DUSEN J, LeBlanc H, Nastasi N, Panescu J, et al
    Identification of SARS-CoV-2 variants in indoor dust.
    PLoS One. 2024;19:e0297172.
    >> Share

  40. GUADALUPE-FERNANDEZ V, Martinez-Solanas E, Sabria-Sunye A, Ferrer-Mikoly C, et al
    Investigating epidemiological distribution (temporality and intensity) of respiratory pathogens following COVID-19 de-escalation process in Catalonia, September 2016-June 2021: Analysis of regional surveillance data.
    PLoS One. 2024;19:e0285892.
    >> Share

  41. VEPACHEDU S, Nurzenska A, Lohiniva AL, Hudi AH, et al
    Understanding COVID-19 vaccination behaviors and intentions in Ghana: A Behavioral Insights (BI) study.
    PLoS One. 2024;19:e0292532.
    >> Share

  42. GALUSHKO V, Riabchyk A
    The demand for online grocery shopping: COVID-induced changes in grocery shopping behavior of Canadian consumers.
    PLoS One. 2024;19:e0295538.
    >> Share

  43. MOLONEY K, Lamprea Montealegre JA, Busch Isaksen TM, Kennedy M, et al
    Assessing community-level impacts of and responses to stay at home orders: The King County COVID-19 community study.
    PLoS One. 2024;19:e0296851.
    >> Share

  44. SIM J, Shin J, Lee HJ, Lee Y, et al
    Impact of coronavirus disease 2019 on cancer care: How the pandemic has changed cancer utilization and expenditures.
    PLoS One. 2024;19:e0296808.
    >> Share

  45. ASADI-POOYA AA, Nemati M, Shahisavandi M, Nemati H, et al
    How does COVID-19 vaccination affect long-COVID symptoms?
    PLoS One. 2024;19:e0296680.
    >> Share

  46. CHAPUT J, Becquet V, Bithorel PL, Baril E, et al
    Medication abortion during the COVID-19 pandemic in France: A research based on the French national health insurance database.
    PLoS One. 2024;19:e0295336.
    >> Share

  47. LI L, Sullivan A, Musah A, Stavrianaki K, et al
    Positive and negative emotions during the COVID-19 pandemic: A longitudinal survey study of the UK population.
    PLoS One. 2024;19:e0297214.
    >> Share

  48. RIUS-SALVADOR M, Garcia-Murria MJ, Rusu L, Bano-Polo M, et al
    Cetylpyridinium chloride and chlorhexidine show antiviral activity against Influenza A virus and Respiratory Syncytial virus in vitro.
    PLoS One. 2024;19:e0297291.
    >> Share


    Vaccine

  49. OKOLI GN, Righolt CH, Zhang G, Van Caeseele P, et al
    A population-based, province-wide, record-linkage interrupted time series analysis of impact of the universal seasonal influenza vaccination policy on seasonal influenza vaccine uptake among 5-64-year-olds in the province of Manitoba, Canada.
    Vaccine. 2024 Feb 14:S0264-410X(24)00104-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  50. AMDISEN L, Pedersen L, Abildgaard N, Benn CS, et al
    The coverage of influenza vaccination and predictors of influenza non-vaccination in Danish cancer patients: A nationwide register-based cohort study.
    Vaccine. 2024 Feb 12:S0264-410X(24)00155-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  51. VALENTIN J, Ingrao F, Rauw F, Lambrecht B, et al
    Protection conferred by an H5 DNA vaccine against highly pathogenic avian influenza in chickens: The effect of vaccination schedules.
    Vaccine. 2024 Feb 12:S0264-410X(23)01422-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  52. WHITAKER HJ, Hassell K, Hoschler K, Power L, et al
    Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients.
    Vaccine. 2024 Feb 10:S0264-410X(24)00150-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  53. WEI J, Tan TC, Moa AM, MacIntyre CR, et al
    Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults.
    Vaccine. 2024 Feb 9:S0264-410X(24)00154-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  54. GRIMA AA, Kwong JC, Richard L, Reid J, et al
    The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Vaccine. 2024 Jan 17:S0264-410X(24)00023-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  55. GEINITZ H, Silberberger E, Spiegl K, Feichtinger J, et al
    SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients.
    Vaccine. 2024 Jan 20:S0264-410X(24)00004-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  56. MITCHELL MM, Klott A, Scholtes J, Braden BB, et al
    Mixed-methods examination of attitudes and behaviors related to COVID-19 vaccines among parents of children with autism and autistic adults.
    Vaccine. 2024 Jan 19:S0264-410X(24)00013-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  57. HICKEN A, Jones P, Menon A, Rozek LS, et al
    Can endorsement by religious leaders move the needle on vaccine hesitancy?
    Vaccine. 2024 Jan 18:S0264-410X(24)00006-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  58. MEMEDOVICH A, Orr T, Hollis A, Salmon C, et al
    Social network risk factors and COVID-19 vaccination: A cross-sectional survey study.
    Vaccine. 2024 Jan 18:S0264-410X(24)00005-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  59. LEMMER Y, Chapman R, Abolnik C, Smith T, et al
    Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
    Vaccine. 2024 Jan 17:S0264-410X(24)00036-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  60. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Warner ND, et al
    Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine.
    Vaccine. 2024 Jan 16:S0264-410X(24)00032-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  61. MCADAM E, Hayashi K, Barker B, Reddon H, et al
    COVID-19 vaccination among young people who use drugs in Vancouver, Canada.
    Vaccine. 2024 Jan 14:S0264-410X(24)00009-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  62. RANDELL M, Sheel M, Dynes M, Li M, et al
    Influence of the COVID-19 pandemic on caregiver beliefs and experiences of routine childhood immunisation in Indonesia.
    Vaccine. 2024;42:812-818.
    >> Share

  63. QURESHI NS, Miller LG, Judge SP, Tran NDT, et al
    Characterizing predictors of COVID-19 vaccine refusal in an urban southern California jail population.
    Vaccine. 2024 Jan 9:S0264-410X(24)00017-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  64. BARZEN G, Rieber F, Stangl K, Hahn K, et al
    mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis.
    Vaccine. 2023 Dec 28:S0264-410X(23)01487-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  65. CENAT JM, Moshirian Farahi SMM, Broussard C, Dalexis RD, et al
    The state of COVID-19 vaccine confidence and need in Black individuals in Canada: Understanding the role of sociodemographic factors, health literacy, conspiracy theories, traumatic stressors and racial discrimination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01246-X. doi: 10.1016/j.vaccine.2023.
    >> Share


    Virus Res

  66. WANG X, Cheng J, Shen L, Chen M, et al
    Rab5c promotes RSV and ADV replication by autophagy in respiratory epithelial cells.
    Virus Res. 2024;341:199324.
    >> Share

  67. HUANG X, Kantonen J, Nowlan K, Nguyen NA, et al
    Mucosal-Associated Invariant T Cells are not susceptible in vitro to SARS-CoV-2 infection but accumulate into the lungs of COVID-19 patients.
    Virus Res. 2024;341:199315.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016